Publications by authors named "Maria Carmen Fernandez-Sanchez de Mora"
Platelet Responses After Tapering and Discontinuation of Fostamatinib in Patients with Immune Thrombocytopenia: A Continuation of the Fostasur Study.
María Eva Mingot-Castellano Gloria García-Donas Rosa María Campos-Álvarez María Carmen Fernández-Sánchez de Mora Josefa Luis-Navarro
J Clin Med
October 2024
Article Synopsis
- Fostamatinib is an approved treatment for adults with chronic immune thrombocytopenia (ITP) but there's limited research on tapering doses and achieving remission after stopping the drug.
- A study involving 61 patients examined the safety and effectiveness of fostamatinib during and after dose tapering, noting that complete platelet response was typically achieved within 28 days.
- Results showed that most patients maintained platelet counts above 100 × 10/L after discontinuation, with a low relapse rate, suggesting that tapering could lead to sustained remission, though further research on tapering strategies is needed.
Immune thrombocytopenia (ITP) is characterized by low platelet counts (PLTs) and an increased risk of bleeding. Fostamatinib, a spleen tyrosine kinase inhibitor, has been approved as a second-line treatment for ITP. Real-world data on fostamatinib are lacking.
View Article and Find Full Text PDFThe Spanish Acquired Hemophilia A (AHA) Registry is intended to update the status of AHA in Spain. One hundred and fifty-four patients were included and retrospectively followed for a median of 12 months. Patients were predominantly male (56.
View Article and Find Full Text PDF